Edding Genor Group Holdings Limited (6998.HK)

Edding Genor Group Holdings Limited, together with its subsidiaries, engages in the research, development, manufacturing, and distribution of biopharmaceutical products in China, the United States, and internationally. The company offers GB491, a differentiated CDK4/6 inhibitor for advanced or metastatic breast cancer; GB261, a novel CD3/CD20 bispecific antibody which is in Phase III clinical trial for autoimmune diseases; and GB263T and GB268, tri-specific antibody candidates which are Phase I clinical trial. It also provides Vancocin for multidrug-resistant gram-positive bacteria; Ceclor for mild to moderate community-acquired bacterial infections in children; Yirui Ping for nebulized inhalation therapy; Vascepa for cardiovascular risk reduction; Mulpleta for reducing bleeding risk; Jing Zhu Da for breast cancer treatment; Recormon for CRA indication; and three siRNA candidates for chronic disease treatment, as well as entinostat and lerociclib hydrochloride tablets. In addition, the company is involved in marketing, commercialization, and trading of pharmaceutical products; research and development of respiratory products; and consultancy and promotion services. Its products are used in oncology, autoimmune, cardiovascular, respiratory, and anti-infective therapeutic areas. Edding Genor Group Holdings Limited was founded in 2001 and is headquartered in Zhuhai, China.